GlycoMimetics is a Maryland-based clinical-stage biotechnology company that develops and commercializes glycobiology therapies for cancer and inflammatory diseases.Read more
GlycoMimetics's revenue is the ranked 21th among it's top 10 competitors. The top 10 competitors average 15.6B. Over the last four quarters, GlycoMimetics's revenue has decreased by 100%. Specifically, in Q2 2021's revenue was $ < 1M; in Q1 2021, it was $1.1M; in Q4 2020, it was $ < 1M; in Q3 2020, GlycoMimetics's revenue was $ < 1M.